Haven't used Abcentra yet?
Ask Trustburn

Questions about Abcentra

Based on 10 reviews, listing data and website checks Β· updated 7 days ago

What is Abcentra?

Abcentra is a clinical-stage biopharmaceutical company based in Los Angeles, California, developing therapeutic antibodies for cardiovascular and inflammatory diseases. The company focuses on preventing heart attacks by targeting coronary artery inflammation through its clinical-stage product, Orticumab. Their mission is to rewrite the narrative around cardiovascular health by providing a new approach to treating coronary artery disease.

What is Orticumab and how does it work?

Orticumab is a first-in-class monoclonal antibody against oxidized LDL that targets vascular inflammation locally. This selective approach aims to maximize the potential benefit to patients while minimizing treatment-associated risks. The therapy is specifically designed to address the buildup of plaque in the arteries that supply blood to the heart muscle.

How does Abcentra's approach differ from other treatments?

Abcentra's targeted approach provides the ability to intervene with precision, which has promise to maximize the benefit to patients while minimizing the risks. This method addresses inflammation in a highly specific manner, distinguishing it from systemic treatments that may come with other potential serious risks and side effects.

What are the current and planned uses for Orticumab?

The company is currently developing Orticumab for secondary prevention after an acute coronary syndrome (ACS). They also plan to expand use into coronary artery disease patients with elevated coronary inflammation. Their pipeline focuses on decreasing the risk of a heart attack in patients with coronary artery disease and inflammation.

What are the recent clinical trial milestones for Abcentra?

Abcentra has demonstrated the potential to reduce coronary inflammation in a phase 2a study. The company recently announced the first patient dosed in the Phase 2b 'FORTIFY' Clinical Trial evaluating Orticumab in patients with cardiovascular disease. They also appointed Dr. Peter Libby as a Board Member as they entered this trial.

Who are the key leaders and board members at Abcentra?

The company's leadership team includes Chris Farina as CEO, Jan Nilsson as Chief Scientific Officer and Board Member, and Prediman K. Shah as Founding Scientist and Board Member. Other board members include Michael H. Davidson, Timothy Wright, Willem Mesdag, and Edward M. Prunchunas.

Where is Abcentra located and what industry does it operate in?

Abcentra is located at 1925 Century Park East in Los Angeles, California. The company operates in the biotechnology industry and has a presence on LinkedIn. They are a US-based entity focused on cardiovascular health.

What do reviewers praise about Abcentra?

Some reviewers on Trustburn praise Abcentra for having a user-friendly website and responsive customer service. Many users mention that the products are of good quality and the overall experience was positive. Some reviewers note that the customer service was helpful and the website is easy to navigate.

What is the Trustburn rating and review distribution for Abcentra?

The Trustburn rating for Abcentra is 3.9 out of 5 from 10 reviews. The rating split includes several 5-star reviews from 2022 and 2023, along with some 3-star and 4-star reviews. The most recent review was posted on November 20, 2023.

What is the primary goal of Abcentra's research?

Abcentra's website states that they are developing Orticumab to decrease the risk of a heart attack in patients with coronary artery disease and inflammation. The company aims to prevent heart attacks by addressing the major driver of heart attacks for patients with coronary artery disease, which is inflammation.

How can visitors engage with Abcentra's team?

Abcentra's website mentions that they are attending cardiovascular events around the globe. They invite visitors to find their team at these events and use the form on their contact page to schedule a meeting.

What is the official website of Abcentra?

The official website of Abcentra is abcentra.com.

Is Abcentra on social media?

Abcentra has official profiles on Linkedin.

Based on reviews, listing data and the company's website. Verify anything important with the company directly.

Erika Shimonski
Reviews 1

I'm quite satisfied with my experience with Abcentra. Their website is easy to navigate and the customer service was prompt and professional. The products I ordered were as expected. I would consider buying from them again.

Questions & Answers

No questions yet β€” be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website β€” its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="abcentra" data-lang="en"></div>
More widgets

About Abcentra

Abcentra is a clinical-stage company developing therapeutic antibodies for cardiovascular and inflammatory diseases

Abcentra: Developing Therapeutic Antibodies for Cardiovascular and Inflammatory Diseases

Abcentra is a clinical-stage company that specializes in the development of therapeutic antibodies for cardiovascular and inflammatory diseases. The company's mission is to improve the lives of patients suffering from these debilitating conditions by providing innovative treatments that target the underlying causes of their symptoms.

At Abcentra, we believe that every patient deserves access to safe, effective, and affordable therapies. That's why we are committed to developing cutting-edge treatments that address unmet medical needs in cardiovascular and inflammatory diseases.

Our team of experienced scientists, researchers, and clinicians work tirelessly to identify new targets for drug development. We use state-of-the-art technologies such as high-throughput screening, structural biology, and bioinformatics to discover novel drug candidates with high specificity and potency.

Once we have identified promising drug candidates, we conduct rigorous preclinical studies to evaluate their safety and efficacy. We use animal models of disease to test our drugs' ability to reduce inflammation or prevent cardiovascular events such as heart attacks or strokes.

If our preclinical studies show promising results, we move on to clinical trials in humans. These trials are designed according to strict regulatory guidelines set by the FDA or other regulatory agencies around the world. Our goal is always to demonstrate safety first before moving on to efficacy endpoints.

We have several ongoing clinical trials at various stages of development for different indications related to cardiovascular disease (CVD) or inflammatory disorders (ID). For example:

- ABT-001: A monoclonal antibody targeting interleukin-6 receptor (IL-6R) for rheumatoid arthritis (RA)

- ABT-002: A monoclonal antibody targeting C-reactive protein (CRP) for atherosclerosis

- ABT-003: A monoclonal antibody targeting tumor necrosis factor-alpha (TNF-alpha) for psoriasis

These trials aim at demonstrating not only the safety but also the efficacy of our drugs in treating these diseases. We are confident that our innovative approach to drug development will lead to new treatments that can improve patients' lives.

Abcentra is also committed to collaborating with other companies, academic institutions, and patient advocacy groups to advance research in cardiovascular and inflammatory diseases. We believe that by working together, we can accelerate the pace of discovery and bring new therapies to market faster.

In conclusion, Abcentra is a clinical-stage company developing therapeutic antibodies for cardiovascular and inflammatory diseases. Our mission is to improve patients' lives by providing innovative treatments that target the underlying causes of their symptoms. We use cutting-edge technologies and rigorous scientific methods to discover novel drug candidates with high specificity and potency. Our ongoing clinical trials aim at demonstrating both safety and efficacy of our drugs in treating different indications related to CVD or ID. We are committed to collaborating with other stakeholders in advancing research in these areas so that we can bring new therapies to market faster.

Address
1925 century park east
Categories
Biotechnology